Market Overview:
The global infectious disease therapeutics market is expected to grow at a CAGR of 7.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of infectious diseases, rising demand for novel therapies, and growing awareness about available treatments. The global infectious disease therapeutics market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into drugs and vaccines. The drugs segment dominates the global infectious disease therapeutics market owing to their high efficacy and widespread use for treating various types of infections. On the basis of application, HIV/AIDS accounts for a major share in terms of revenue due to its high prevalence across all regions globally; however, other applications such as influenza are expected to witness significant growth during the forecast period owing to increasing awareness about available treatments and rising incidence rates.
Product Definition:
Infectious Disease Therapeutics is the branch of medicine that deals with the treatment and prevention of infection. Infection can be caused by bacteria, viruses, or parasites, and can lead to a range of diseases from mild to life-threatening. Infectious Disease Therapeutics is important because it provides treatments for infections that can cause serious illness and death.
Drugs:
Drugs, it's usage and growth factor in infectious disease therapeutics market is expected to register significant growth over the forecast period. Increasing prevalence of chronic diseases such as HIV AIDS, cancer & diabetes coupled with rising demand for effective treatment therapies are some high impact rendering drivers for this market.
Global drugs, it's usage.
Vaccines:
Vaccines are biological agents used to stimulate the body's immune system to act against a specific disease-causing microorganism. The term vaccine commonly refers to a preparation of dead or living organisms, which when introduced into the human body, enables the immune system to recognize and attack similar pathogens.
Application Insights:
The global infectious disease therapeutics market is segmented by application into HIV/AIDS, influenza, hepatitis, malaria, tuberculosis and others. The other applications include bacterial infections and parasitic diseases. Among these other applications are the largest segments occupied by the others that includes cholera & diarrhea epidemics as well as hookworm disease. These diseases have been a major concern for many years especially in developing countries such as India and China where they account for around 20% of all deaths due to infectious diseases.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of players, high awareness levels coupled with the availability of effective treatment for infectious diseases are some factors attributing to its largest share. Moreover, increasing government initiatives and rising investments by companies in R&D activities for development of new therapies are expected to drive growth over the forecast period.
Asia Pacific is estimated to be one of the fastest growing regions during the forecast period owing to increasing prevalence rates for malaria, dengue fever and other mosquito-borne illnesses such as West Nile Virus (WNV), Japanese Encephalitis (JE) and Zika virus disease.
Growth Factors:
- Increasing incidence of infectious diseases: The increasing incidence of infectious diseases is one of the key growth drivers for the global infectious disease therapeutics market. According to a study by the World Health Organization (WHO), every year, around 2 million people die from infections caused by antibiotic-resistant bacteria. This number is expected to increase in future due to the increasing prevalence of antibiotic-resistant bacteria.
- Rising demand for novel antibiotics: The rising demand for novel antibiotics is another key growth driver for the global infectious disease therapeutics market. Novel antibiotics are those that are effective against resistant strains of bacteria and have low toxicity levels, which makes them suitable for use in humans and animals alike. They are also less likely to cause resistance than older antibiotics, making them an important tool in combating antimicrobial resistance (AMR).
- Growing awareness about AMR: The growing awareness about AMR among healthcare professionals and patients is another key growth driver for the global infectious disease therapeutics market. AMR occurs when microorganisms such as bacteria, viruses, and parasites develop resistance to drugs used to treat infections caused by them, making these infections increasingly difficult or even impossible to treat effectively with available medicines.. As a result, there is an urgent need for new drugs that can combat these resistant strains effectively.. This has led to an increased focus on research and development activities aimed at discovering new antibacterial agents..
Scope Of The Report
Report Attributes
Report Details
Report Title
Infectious Disease Therapeutics Market Research Report
By Type
Drugs, Vaccines
By Application
HIV/AIDS, Influenza, Hepatitis, Malaria, Tuberculosis, Others
By Companies
Novartis AG, Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical Inc., F. Hoffmann-La Roche Ltd., BioCryst Pharmaceuticals Inc., Merck & Co. Inc., Boehringer Ingelheim GmbH
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Infectious Disease Therapeutics Market Report Segments:
The global Infectious Disease Therapeutics market is segmented on the basis of:
Types
Drugs, Vaccines
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
HIV/AIDS, Influenza, Hepatitis, Malaria, Tuberculosis, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis AG
- Gilead
- GlaxoSmithKline plc
- Janssen Pharmaceutical Inc.
- F. Hoffmann-La Roche Ltd.
- BioCryst Pharmaceuticals Inc.
- Merck & Co. Inc.
- Boehringer Ingelheim GmbH
Highlights of The Infectious Disease Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Drugs
- Vaccines
- By Application:
- HIV/AIDS
- Influenza
- Hepatitis
- Malaria
- Tuberculosis
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Infectious Disease Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Infectious Disease Therapeutics is a field of medicine that deals with the prevention, diagnosis and treatment of infectious diseases.
Some of the major players in the infectious disease therapeutics market are Novartis AG, Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical Inc., F. Hoffmann-La Roche Ltd., BioCryst Pharmaceuticals Inc., Merck & Co. Inc., Boehringer Ingelheim GmbH.
The infectious disease therapeutics market is expected to register a CAGR of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Infectious Disease Therapeutics Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Infectious Disease Therapeutics Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Infectious Disease Therapeutics Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Infectious Disease Therapeutics Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Infectious Disease Therapeutics Market Size & Forecast, 2018-2028 4.5.1 Infectious Disease Therapeutics Market Size and Y-o-Y Growth 4.5.2 Infectious Disease Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Infectious Disease Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Infectious Disease Therapeutics Market Size Forecast by Type
5.2.1 Drugs
5.2.2 Vaccines
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Infectious Disease Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Infectious Disease Therapeutics Market Size Forecast by Applications
6.2.1 HIV/AIDS
6.2.2 Influenza
6.2.3 Hepatitis
6.2.4 Malaria
6.2.5 Tuberculosis
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Infectious Disease Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Infectious Disease Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Infectious Disease Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Infectious Disease Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Infectious Disease Therapeutics Market Size Forecast by Type
9.6.1 Drugs
9.6.2 Vaccines
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Infectious Disease Therapeutics Market Size Forecast by Applications
9.10.1 HIV/AIDS
9.10.2 Influenza
9.10.3 Hepatitis
9.10.4 Malaria
9.10.5 Tuberculosis
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Infectious Disease Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Infectious Disease Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Infectious Disease Therapeutics Market Size Forecast by Type
10.6.1 Drugs
10.6.2 Vaccines
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Infectious Disease Therapeutics Market Size Forecast by Applications
10.10.1 HIV/AIDS
10.10.2 Influenza
10.10.3 Hepatitis
10.10.4 Malaria
10.10.5 Tuberculosis
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Infectious Disease Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Infectious Disease Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Infectious Disease Therapeutics Market Size Forecast by Type
11.6.1 Drugs
11.6.2 Vaccines
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Infectious Disease Therapeutics Market Size Forecast by Applications
11.10.1 HIV/AIDS
11.10.2 Influenza
11.10.3 Hepatitis
11.10.4 Malaria
11.10.5 Tuberculosis
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Infectious Disease Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Infectious Disease Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Infectious Disease Therapeutics Market Size Forecast by Type
12.6.1 Drugs
12.6.2 Vaccines
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Infectious Disease Therapeutics Market Size Forecast by Applications
12.10.1 HIV/AIDS
12.10.2 Influenza
12.10.3 Hepatitis
12.10.4 Malaria
12.10.5 Tuberculosis
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Infectious Disease Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Infectious Disease Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Infectious Disease Therapeutics Market Size Forecast by Type
13.6.1 Drugs
13.6.2 Vaccines
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Infectious Disease Therapeutics Market Size Forecast by Applications
13.10.1 HIV/AIDS
13.10.2 Influenza
13.10.3 Hepatitis
13.10.4 Malaria
13.10.5 Tuberculosis
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Infectious Disease Therapeutics Market: Competitive Dashboard
14.2 Global Infectious Disease Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis AG
14.3.2 Gilead
14.3.3 GlaxoSmithKline plc
14.3.4 Janssen Pharmaceutical Inc.
14.3.5 F. Hoffmann-La Roche Ltd.
14.3.6 BioCryst Pharmaceuticals Inc.
14.3.7 Merck & Co. Inc.
14.3.8 Boehringer Ingelheim GmbH